One important metric to look for in a stock is an 80 or higher Relative Strength Rating. Sanofi ADR cleared that benchmark Thursday, with a jump from 79 to 82 Thursday.
Looking For The Best Stocks To Buy And Watch? Start Here
This exclusive rating from Investor's Business Daily measures price performance with a 1 (worst) to 99 (best) score. The score shows how a stock's price movement over the trailing 52 weeks stacks up against all the other stocks in our database.
Over 100 years of market history shows that the best stocks typically have an RS Rating north of 80 in the early stages of their moves.
Sanofi ADR is trying to complete a consolidation with a 60.12 entry. See if the stock can clear the breakout price in volume at least 40% above average.
The company posted -29% EPS growth last quarter. Revenue rose 2%.
Sanofi ADR holds the No. 6 rank among its peers in the Medical-Ethical Drugs industry group. Novartis ADR, Protagonist Therapeutics and Phibro Animal Health are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Improved Technical Action?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
